MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

• Sponsor: Yale University (Other)
• Overall Status: Completed
• CT.gov ID: NCT02085070
• Collaborator: (none)
• Enrollment: 65
• Location: 1
• Arms: 2
• Duration (Months): 71.9
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.

Condition or Disease	Intervention/Treatment	Phase
Melanoma; Non-Small Cell Lung Cancer; Brain Metastases	Drug: MK-3475	Phase 2

Detailed Description

While recent advances in the treatment of metastatic melanoma and NSCLC (non-small cell lung cancer) with agents targeting PD-1 are striking, there remains a significant need to develop therapies for patients with untreated brain metastases who were excluded from prior trials with MK-3475 and the majority of other studies in these diseases. The brain is a common site of disease spread in many solid tumors, most notably metastatic melanoma and NSCLC. 10-40% of patients with metastatic melanoma develop brain metastases during their lifetime and >75% have brain metastases at autopsy. Overall, historical melanoma patient cohorts have reported a median survival of patients with brain metastases in the order of 2.5 - 4 months despite use of whole brain radiation therapy (WBRT) and surgery. One older patient series showed a median survival of < 4 months in melanoma patients with brain metastases and a neurological death rate of >30% despite the treatment of intracranial metastases with whole brain radiation therapy (WBRT). Among those with NSCLC, 10% have brain metastases at presentation and another 30% develop them over the course of their disease. Survival after the development of brain metastases is as dismal in those with NSCLC as it is for melanoma. Multifocal disease is common in both of these diseases, with about half of patients with CNS disease presenting with more than one brain lesion.

Patients with untreated brain metastases have been excluded from most clinical trials of systemic therapy for two reasons: (1) historically their prognosis has been poor (overall survival ≤ 4 months) and (2) experimental drugs are presumed to not penetrate the blood brain barrier (BBB) or BBB penetration is not well studied. In melanoma, for example, one phase III study evaluating ipilimumab excluded patients with untreated brain metastases and another study evaluating ipilimumab and dacarbazine excluded all patients with a history of brain metastases, regardless of prior treatment. A subsequent trial with ipilimumab for patients with untreated brain metastases indeed showed that the drug had some activity in treating CNS disease. In the initial vemurafenib studies, patients with progressing or unstable CNS metastases were excluded. The pivotal BRIM-3 trial excluded patients with brain metastases unless metastases had been definitively treated more than three months prior to trial enrollment. Both temodar and sorafenib cross the BBB. Initial studies with sorafenib alone and in combination with chemotherapy excluded patients with active brain metastases. A combination study of temodar and sorafenib in patients with or without brain metastases showed modest activity in patients without a history of prior temodar, and was thought to be favorable in part due to local therapies. Although a number of studies have been conducted for melanoma patients with untreated brain metastases using established therapies, most initial clinical trials with novel agents exclude these patients. A recent trial with dabrafenib, an inhibitor of mutated B-raf, is an exception to the long-standing paradigm. A phase I/II study of this agent included a subset of patients with untreated brain metastases. At the 2010 meeting of the European Society for Medical Oncology, Long et al reported that nine of the ten patients with untreated cerebral metastases enrolled in this trial had shrinkage of their brain lesions. This was the basis for a recent phase II trial of dabrafenib specific for patients with untreated brain metastases61. In NSCLC, a small number of trials have shown that combination chemotherapy regimens can induce a response in the CNS with untreated brain metastases with a median PFS up to 4 months. These studies demonstrate that asymptomatic brain metastases, similar to asymptomatic metastases in other sites, can be treated systemically on clinical trials, and that drug activity in the CNS is not necessarily different than in other metastatic locations.

Current standard of care for brain metastases that require immediate local intervention (based on symptoms, location, size, or other concerning features) is craniotomy with resection or radiation therapy. As an adjunct to standard craniotomy, LITT is emerging as a new, minimally invasive local therapy to treat previously surgically inaccessible brain metastases. Not only is cell death instantaneous, thus decreasing the risk of delayed intra-tumoral hemorrhage, but another theoretical advantage of using LITT as part of management of brain metastases is that the hyperthermia breaks down the blood brain barrier at the edge of the coagulation region thereby possibly increasing access of chemotherapeutic agents into the lesion. In patients in whom either craniotomy or LITT are performed, biopsies of tumor and surrounding normal brain can also be obtained at the time of local therapy.

The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or NSCLC. Given the promising initial results of MK-3475 in these diseases but the lack of data in patients with untreated brain metastases thus far, this trial will study treatment in this patient population. Additionally, for patients with melanoma this trial requires local therapy with craniotomy or LITT to at least 1 brain lesion prior to systemic therapy, thereby allowing the acquisition of brain tumor tissue for correlative studies on biomarkers that may be predictive of clinical response in the CNS and systemically. There will also be a biopsy of an extra-cerebral metastasis when feasible, particularly when tissue from the brain lesion is not obtained in patients with NSCLC.

Upon results entry, the primary outcome measure was aligned as originally presented in the study protocol (attached with results).

Study Design

• Study Type: Interventional
• Actual Enrollment: 65 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
• Study Start Date: Mar 1, 2014
• Actual Primary Completion Date: Feb 27, 2020
• Actual Study Completion Date: Feb 27, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Melanoma patients After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the "surgical lesion". All other eligible brain lesions will be considered "clinically evaluable lesions" and will be followed by modified RECIST (mRECIST) criteria to determine best response.	Drug: MK-3475; IV MK-3475
Other: Non-small cell lung cancer patients NSCLC patients are not required to have a "surgical lesion" but must have at least one "clinically evaluable lesion" in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis.	Drug: MK-3475; IV MK-3475

Outcome Measures

Primary Outcome Measures

1. Overall Response in the Brain by mRECIST [8 weeks]

   RECIST criteria v1.1 was modified to account for differences in measuring the response of clinically evaluable brain lesions as opposed to systemic lesions (modified RECIST, or mRECIST). Size was considered the tumor's largest diameter. Measurements from multiple lesions were summed to calculate the sum of the diameters (SD). The SD calculated on a baseline scan performed within 28 days of study drug initiation was used as a reference to determine the objective response of the clinically evaluable lesions. mRECIST differ from RECIST v1.0 in allowing lesions measuring 5mm or less for response evaluation, provided that the MRI slice thickness was no more than 2.5mm. Seeing that the primary trial endpoint was brain metastasis response, up to 5 lesions were used for evaluation. Complete response (CR) constitutes complete disappearance of all target lesions, partial response (PR) constitutes >= 30% decrease in the sum of the sum of the largest diameter of target

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 99 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Biopsy proven metastatic melanoma or NSCLC as follows:

2. Patients with metastatic melanoma must have untreated brain metastases including:

• At least one cerebral metastasis that requires local intervention and is amenable to craniotomy or LITT therapy either due to symptoms, lesion size, location, edema or hemorrhage ("surgical lesion"). Alternatively, a patient may be eligible if a cerebral metastasis was resected or biopsied any time prior to enrollment and there is tumor tissue available for analysis.

• At least one cerebral metastasis that is at least 5 mm AND twice the MRI slice thickness, but less than 20 mm, that is asymptomatic and does not require local therapy at the time of enrollment ("clinically evaluable lesion(s)"). OR

1. Patients with stage IV NSCLC with at least one cerebral metastasis that is at least 5 mm AND twice the MRI slice thickness, but less than 20 mm, that is asymptomatic and does not require local therapy at the time of enrollment ("clinically evaluable lesion(s)").

2. Age ≥18

3. ECOG performance status < 2

4. Any number of previous treatments with the exception of previous inhibitors of PD-1, PD-L1, or PD-L2; other prior systemic therapies must have been administered at least 2 weeks before administration of MK-3475 with the exception of bevacizumab which must have been administered at least 4 weeks prior to MK-3475. Patients are not required to have had prior systemic therapy. The exception to this is patients with NSCLC who test negative for PD-L1 expression or are unevaluable for PD-L1 expression must have received prior platinum-based chemotherapy for entry into Cohort 2. Note: Ipilimumab treatment should have been administered at least 4 weeks prior to the start of MK-3475.

5. Life expectancy of at least 3 months

6. A history of previously treated brain metastases is allowed, provided that at least 14 days have lapsed between radiation and initiation of MK-3475. Any lesion present at the time of WBRT or included in the stereotactic radiotherapy field (or within 2mm of the treated lesion) will NOT be considered evaluable unless it is new or documented to have progressed since treatment.

7. PD-L1 expression in tumor tissue from any site is required for patients with NSCLC for entry into Cohort 1. Tumor tissue must be obtained after the last systemic therapy. PD-L1 expression will be analyzed by a Merck assay. For NSCLC Cohort 2, patients may test PD-L1 negative or may be unevaluable for PD-L1 expression (i.e. insufficient tumor tissue). PD-L1 expression is not required for patients with melanoma, but melanoma patients are required to submit an extra-cerebral specimen for analysis, unless it is not feasible to obtain one.

8. Patients must have normal organ and marrow function as defined per protocol.

9. For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of MK-3475.

10. For men with female partners of childbearing potential, agreement to use a latex condom, and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of MK-3475.

11. Negative serum or urine pregnancy test within 72 hours of commencement of treatment in premenopausal women.

12. Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Symptomatic brain metastases. Symptoms may be present from the surgical lesion prior to resection or LITT but must have resolved by the time of administration of study drug.

2. Patients with brain metastases for whom complete surgical resection is clinically appropriate.

3. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy to the lung or brain within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Previous radiation to other sites may be completed at any time prior to initiation of MK-3475.

4. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

5. Note: Toxicity that has not recovered to ≤ Grade 1 is allowed if it meets the inclusion requirements for laboratory parameters.

6. Has had prior treatment with any other anti-PD-1 or PD-L1 or PD-L2 agent or an antibody targeting other immune-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against IDO, PD-L1, IL-2R, GITR. Prior ipilimumab, IL2, bevacizumab and adoptive cell therapy is allowed.

7. The use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least 2 weeks. Low-dose steroid use (≤10 mg of prednisone or equivalent) as corticosteroid replacement therapy is allowed

8. Has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

9. Presence of leptomeningeal disease

10. Has an active automimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of inhaled steroids or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.

11. Pregnancy or breast feeding. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-3475, breastfeeding must be discontinued if the mother is treated with MK-3475.

1. Patients may not be receiving any other investigational agents and may not have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.

2. Either a concurrent condition (including medical illness, such as active infection requiring treatment with intravenous antibiotics or the presence of laboratory abnormalities) or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or a medical condition that confounds the ability to interpret data from the study.

3. Concurrent, active malignancies in addition to those being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)

4. Any contraindication to MRI (i.e. patients with pacemakers or other metal implanted medical devices). An MRI safety questionnaire is required prior to MR imaging.

5. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis

6. Has a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infection.

7. Has received a live vaccine within 30 days prior to the first dose of trial treatment.

8. Evidence of interstitial lung disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Smilow Cancer Center at Yale New Haven Hospital	New Haven	Connecticut	United States	06510

Sponsors and Collaborators

• Yale University

Investigators

• Principal Investigator: Harriet Kluger, MD, Yale University

Study Documents (Full-Text)

• Informed Consent Form - Feb 24, 2020
• Study Protocol and Statistical Analysis Plan - Feb 22, 2019

More Information

Publications

• Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.
• Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020 May;21(5):655-663. doi: 10.1016/S1470-2045(20)30111-X. Epub 2020 Apr 3.
• Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8.

• Responsible Party: Harriet Kluger, Associate Professor, Internal Medicine, Oncology, Yale University
• ClinicalTrials.gov Identifier: NCT02085070
• Other Study ID Numbers: 1401013290; IND 121564
• First Posted: Mar 12, 2014
• Last Update Posted: Mar 24, 2021
• Last Verified: Feb 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Brain Neoplasms; Pembrolizumab

Study Results

Participant Flow

Recruitment Details	29 NSCLC patients were ineligible based on PD-L1.
Pre-assignment Detail	Patients were assigned to a cohort based on tumor type.

Arm/Group Title	Melanoma Patients	Non-small Cell Lung Cancer Patients
Arm/Group Description	After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the "surgical lesion". All other eligible brain lesions will be considered "clinically evaluable lesions" and will be followed by modified RECIST (mRECIST) criteria to determine best response. MK-3475: IV MK-3475	NSCLC patients are not required to have a "surgical lesion" but must have at least one "clinically evaluable lesion" in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis. MK-3475: IV MK-3475
Period Title: Overall Study
STARTED	23	42
COMPLETED	23	42
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Melanoma Patients	Non-small Cell Lung Cancer Patients	Total
Arm/Group Description	After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the "surgical lesion". All other eligible brain lesions will be considered "clinically evaluable lesions" and will be followed by modified RECIST (mRECIST) criteria to determine best response. MK-3475: IV MK-3475	NSCLC patients are not required to have a "surgical lesion" but must have at least one "clinically evaluable lesion" in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis. MK-3475: IV MK-3475	Total of all reporting groups
Overall Participants	23	42	65
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	10 43.5%	27 64.3%	37 56.9%
>=65 years	13 56.5%	15 35.7%	28 43.1%
Sex: Female, Male (Count of Participants)
Female	8 34.8%	28 66.7%	36 55.4%
Male	15 65.2%	14 33.3%	29 44.6%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	4 9.5%	4 6.2%
Not Hispanic or Latino	23 100%	36 85.7%	59 90.8%
Unknown or Not Reported	0 0%	2 4.8%	2 3.1%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	1 2.4%	1 1.5%
Native Hawaiian or Other Pacific Islander	0 0%	1 2.4%	1 1.5%
Black or African American	0 0%	1 2.4%	1 1.5%
White	23 100%	35 83.3%	58 89.2%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	4 9.5%	4 6.2%
Region of Enrollment (participants) [Number]
United States	23 100%	42 100%	65 100%

Outcome Measures

1. Primary Outcome

Title	Overall Response in the Brain by mRECIST
Description	RECIST criteria v1.1 was modified to account for differences in measuring the response of clinically evaluable brain lesions as opposed to systemic lesions (modified RECIST, or mRECIST). Size was considered the tumor's largest diameter. Measurements from multiple lesions were summed to calculate the sum of the diameters (SD). The SD calculated on a baseline scan performed within 28 days of study drug initiation was used as a reference to determine the objective response of the clinically evaluable lesions. mRECIST differ from RECIST v1.0 in allowing lesions measuring 5mm or less for response evaluation, provided that the MRI slice thickness was no more than 2.5mm. Seeing that the primary trial endpoint was brain metastasis response, up to 5 lesions were used for evaluation. Complete response (CR) constitutes complete disappearance of all target lesions, partial response (PR) constitutes >= 30% decrease in the sum of the sum of the largest diameter of target
Time Frame	8 weeks

Outcome Measure Data

Analysis Population Description

modified RECIST 1.1 was used to determine response

Arm/Group Title	Melanoma Patients	Non-small Cell Lung Cancer Patients
Arm/Group Description	After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the "surgical lesion". All other eligible brain lesions will be considered "clinically evaluable lesions" and will be followed by modified RECIST (mRECIST) criteria to determine best response. MK-3475: IV MK-3475	NSCLC patients are not required to have a "surgical lesion" but must have at least one "clinically evaluable lesion" in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis. MK-3475: IV MK-3475
Measure Participants	23	42
progression/stable	17 73.9%	31 73.8%
better response	6 26.1%	11 26.2%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Non-small Cell Lung Cancer Patients
	Comments	Each group was assessed individually. The primary goal of this study is to determine the efficacy of MK-3475 in patients with untreated brain metastases from NSCLC. The primary endpoint is the brain metastasis response rate (BMRR). A drug with minimal activity would be expected to have a BMRR of 10%.
	Type of Statistical Test	Superiority
	Comments	A response of > 10% of patients was defined as superior.
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	% response
	Estimated Value	29.7
	Confidence Interval	(2-Sided) 95%; 15.9 to 47.0
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Melanoma Patients
	Comments	Each group was assessed individually. The primary goal of this study is to determine the efficacy of MK-3475 in patients with untreated brain metastases from melanoma. The primary endpoint is the brain metastasis response rate (BMRR). A drug with minimal activity would be expected to have a BMRR of 10%.
	Type of Statistical Test	Superiority
	Comments	A response of > 10% of patients was defined as superior.
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	% of patients
	Estimated Value	26.0
	Confidence Interval	(2-Sided) 95%; 10.0 to 48.0
	Parameter Dispersion	Type: Value:
	Estimation Comments

Adverse Events

Time Frame	2 Years
Arm/Group Title	Melanoma Patients		Non-small Cell Lung Cancer Patients
Arm/Group Description	After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the "surgical lesion". All other eligible brain lesions will be considered "clinically evaluable lesions" and will be followed by modified RECIST (mRECIST) criteria to determine best response. MK-3475: IV MK-3475		NSCLC patients are not required to have a "surgical lesion" but must have at least one "clinically evaluable lesion" in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis. MK-3475: IV MK-3475
All Cause Mortality
	Melanoma Patients		Non-small Cell Lung Cancer Patients
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	16/23 (69.6%)		35/42 (83.3%)
Serious Adverse Events
	Melanoma Patients		Non-small Cell Lung Cancer Patients
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/23 (21.7%)		5/42 (11.9%)
Endocrine disorders
Adrenal Insufficienvy	0/23 (0%)	0	1/42 (2.4%)	1
Gastrointestinal disorders
Colitis	0/23 (0%)	0	1/42 (2.4%)	1
General disorders
Fever	1/23 (4.3%)	1	0/42 (0%)	0
Metabolism and nutrition disorders
Hypokalemia	0/23 (0%)	0	1/42 (2.4%)	1
Nervous system disorders
Seizure	1/23 (4.3%)	1	0/42 (0%)	0
Psychiatric disorders
Confusion	2/23 (8.7%)	2	0/42 (0%)	0
Renal and urinary disorders
Acute Kidney Injury	0/23 (0%)	0	1/42 (2.4%)	1
Respiratory, thoracic and mediastinal disorders
Pneumonitis	0/23 (0%)	0	2/42 (4.8%)	2
Skin and subcutaneous tissue disorders
Rash	1/23 (4.3%)	1	0/42 (0%)	0
Other (Not Including Serious) Adverse Events
	Melanoma Patients		Non-small Cell Lung Cancer Patients
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	13/23 (56.5%)		35/42 (83.3%)
Endocrine disorders
Hypothyroidism	1/23 (4.3%)	1	6/42 (14.3%)	8
Eye disorders
Floaters	0/23 (0%)	0	4/42 (9.5%)	5
Gastrointestinal disorders
Abdominal pain	2/23 (8.7%)	2	6/42 (14.3%)	6
Colitis	2/23 (8.7%)	2	0/42 (0%)	0
Constipation	2/23 (8.7%)	2	21/42 (50%)	30
Diarrhea	3/23 (13%)	3	14/42 (33.3%)	26
Nausea	7/23 (30.4%)	7	12/42 (28.6%)	17
Vomiting	2/23 (8.7%)	2	4/42 (9.5%)	6
Dyspepsia	0/23 (0%)	0	3/42 (7.1%)	3
Gastroesophageal reflux disease	0/23 (0%)	0	3/42 (7.1%)	4
General disorders
Chills	2/23 (8.7%)	2	1/42 (2.4%)	1
Fatigue	13/23 (56.5%)	13	35/42 (83.3%)	65
Edema limbs	0/23 (0%)	0	10/42 (23.8%)	14
Fever	1/23 (4.3%)	1	3/42 (7.1%)	5
Non-cardiac chest pain	0/23 (0%)	0	5/42 (11.9%)	5
Investigations
Alanine aminotransferase increased	0/23 (0%)	0	3/42 (7.1%)	5
Aspartate aminotransferase increased	0/23 (0%)	0	3/42 (7.1%)	4
Creatinine increased	0/23 (0%)	0	3/42 (7.1%)	4
Metabolism and nutrition disorders
Anorexia	0/23 (0%)	0	17/42 (40.5%)	25
Musculoskeletal and connective tissue disorders
Arthralgia	2/23 (8.7%)	2	3/42 (7.1%)	3
Back pain	2/23 (8.7%)	2	18/42 (42.9%)	26
Pain	3/23 (13%)	4	4/42 (9.5%)	10
Bone pain	0/23 (0%)	0	3/42 (7.1%)	5
Chest wall pain	0/23 (0%)	0	3/42 (7.1%)	4
Muscle weakness lower limb	1/23 (4.3%)	1	4/42 (9.5%)	6
Neck pain	0/23 (0%)	0	3/42 (7.1%)	3
Pain in extremity	1/23 (4.3%)	1	13/42 (31%)	25
Nervous system disorders
Ataxia	3/23 (13%)	3	0/42 (0%)	0
Cognitive disturbance	2/23 (8.7%)	2	2/42 (4.8%)	2
Confusion	2/23 (8.7%)	2	0/42 (0%)	0
Dizziness	2/23 (8.7%)	2	10/42 (23.8%)	13
Dysphasia	2/23 (8.7%)	2	0/42 (0%)	0
Gait disturbance	2/23 (8.7%)	2	0/42 (0%)	0
Headache	3/23 (13%)	3	15/42 (35.7%)	30
Seizure	1/23 (4.3%)	1	3/42 (7.1%)	5
Psychiatric disorders
Anxiety	1/23 (4.3%)	1	9/42 (21.4%)	11
Depression	0/23 (0%)	0	3/42 (7.1%)	3
Insomnia	0/23 (0%)	0	7/42 (16.7%)	8
Respiratory, thoracic and mediastinal disorders
Cough	3/23 (13%)	3	26/42 (61.9%)	42
Nasal congestion	2/23 (8.7%)	2	2/42 (4.8%)	3
Allergic rhinitis	1/23 (4.3%)	1	5/42 (11.9%)	7
Dyspnea	0/23 (0%)	0	21/42 (50%)	28
Skin and subcutaneous tissue disorders
Pruritus	4/23 (17.4%)	4	5/42 (11.9%)	9
Rash maculo-papular	3/23 (13%)	3	10/42 (23.8%)	11
Vascular disorders
Hypertension	0/23 (0%)	0	7/42 (16.7%)	8
Thromboembolic event	0/23 (0%)	0	6/42 (14.3%)	7

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.